Medscape

Resmetirom Reduces Liver, CV Risk Factors in NASH With Cirrhosis

WASHINGTON — In patients with cirrhosis associated with non-alcoholic steatohepatitis (NASH), 1 year of treatment with the investigational oral thyromimetic agent resmetirom (MGL-3196) was safe and ...
UUHC Health Feed

Non-Alcoholic Steatohepatitis (NASH): What Is It and Am I at Risk?

It is widely known that alcohol use can cause liver damage, but other risk factors make it possible to develop liver disease even if you drink little to no alcohol. Non-alcoholic steatohepatitis (NASH ...
Medscape

Semaglutide Doesn't Improve Fibrosis in NASH-Related Cirrhosis

Semaglutide didn't significantly improve liver fibrosis or achieve resolution of nonalcoholic steatohepatitis (NASH)–related compensated cirrhosis compared with placebo, according to a phase 2 trial.
Healthline

What Is NASH (Now Called MASH)?

Nonalcoholic steatohepatitis (NASH) is a type of nonalcoholic fatty liver disease (NAFLD). It involves a buildup of fat in your liver, inflammation, and damage. Nonalcoholic steatohepatitis (NASH) is ...
The Financial

Global study to spur new liver cirrhosis medicines

The FINANCIAL — The ADVANCE (Accelerating Discovery: Actionable NASH Cirrhosis Endpoints) study will follow 200 patients with cirrhosis – scarring caused by long-term damage of the liver – to uncover ...
Nasdaq

Galectin Therapeutics’ Statement Following the Recent 2023 Emerging Topic Conference on NASH Cirrhosis, Sponsored by the American Association for the Study of Liver Diseases

NORCROSS, Ga., April 18, 2023 (GLOBE NEWSWIRE) -- Galectin Therapeutics, Inc. (NASDAQ: GALT), the leading developer of therapeutics that target galectin proteins, attended the 2023 Emerging Topic ...
MedCity News

A First for Fatty Liver: FDA Approves Madrigal Pharma NASH Drug

A chronic metabolic disease in which fat buildup leads to worsening liver function that can ultimately require an organ transplant now has its first FDA-approved therapy, a once-daily pill developed ...
News Medical

Owlstone Medical presents data demonstrating progress in development of breath biopsy tests for liver cirrhosis and NASH

Owlstone Medical (“Owlstone”), the global leader in Breath Biopsy ® for applications in early disease detection and precision medicine, today announced new data on the development of novel tests for ...
Seeking Alpha

Galectin Therapeutics to Present Data on Liver Cirrhosis at the 9th Edition of the Paris NASH meeting, at Institut Pasteur, September 7th & 8th 2023

NORCROSS, Ga., Sept. 07, 2023 (GLOBE NEWSWIRE) -- Galectin Therapeutics Inc. (GALT), the leading developer of therapeutics that target galectin proteins, announced today the Company will participate ...
Healthline

Cirrhosis Hypoglycemia: Causes, Symptoms, and Treatments

Cirrhosis (liver scarring) can lead to hypoglycemia (low blood sugar). Treating any underlying conditions, avoiding alcohol, eating nutritious foods, and monitoring blood sugar levels can help. An ...
Hosted on MSN

Here's Why Liver Cirrhosis Is Rising, Even Among Non-Drinkers

Once primarily linked to heavy alcohol consumption, liver cirrhosis is now increasingly affecting people who have never had a drink. Experts are warning of a silent but growing health crisis driven by ...